TF and cancer: Garen and Hu have targeted TF using its natural ligand fVII for the development of Icon (fVII/IgG1 Fc) immunotherapy [2-4], which showed dramatic efficacy for treatment of several types of cancer [2-5], wMD [7,8] and endometriosis [9] in animal models.